Arrested development.

Newer generation androgen blockers have changed the face of treatment for metastatic prostate cancer, providing an effective and relatively well-tolerated chemo-free therapeutic strategy. So what’s next when patients progress on something like apalutamide or enzalutamide? In keeping with the “chemo-free” theme, here is a retrospective look at 35 such men who received subsequent stereotactic ablative radiation (SABR) to at least one site of progressive disease within the Harvard medical system. All were castrate resistant (i.e., PSA was rising despite testosterone being <50 ng/mL). The co-primary endpoints following SABR were achieving a PSA reduction of at least 50%, which occurred in roughly two-thirds of men, and median progression-free survival, which was 9 months. Perhaps most interesting was the stand-out group achieving long term disease control (median 13 months) as seen among the 22 patients who had all sites of progressive disease treated. | Brennan, Adv Radiat Oncol 2021

Comments

Popular Posts